Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule currently in a Phase 1b clinical trial investigating its potential to treat platinum resistant, ARID1a-mutated ovarian carcinoma. The FDA granted Fast Track Designation to the NXP800 development program in platinum resistant, ARID1a-mutated ovarian carcinoma, and Orphan Drug Designation for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule SRC/YES1 kinase family (SFK) inhibitor currently in a Phase 1a dose escalation clinical trial.
Company profile
Ticker
NVCT
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
NUVECTIS THERAPEUTICS INC. ...
IRS number
862405608
NVCT stock data
Latest filings (excl ownership)
8-K
Other Events
29 Aug 24
10-Q
2024 Q2
Quarterly report
6 Aug 24
8-K
Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights
6 Aug 24
8-K
Submission of Matters to a Vote of Security Holders
13 Jun 24
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
7 May 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
10-K
2023 FY
Annual report
5 Mar 24
8-K
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
5 Mar 24
Latest ownership filings
4
Matthew L. Kaplan
13 Jun 24
4
Kenneth Hoberman
13 Jun 24
4
James F Oliviero III
13 Jun 24
4
RON BENTSUR
15 May 24
4
RON BENTSUR
13 May 24
4
Enrique Poradosu
13 May 24
4
Shay Shemesh
13 May 24
4
RON BENTSUR
19 Mar 24
SC 13G/A
Mosseri Marlio Charles
28 Feb 24
SC 13G
Pontifax Management 4 G.P. (2015) Ltd.
6 Feb 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 18.12 mm | 18.12 mm | 18.12 mm | 18.12 mm | 18.12 mm | 18.12 mm |
Cash burn (monthly) | 449.33 k | 540.33 k | 1.55 mm | 1.84 mm | 1.01 mm | 1.21 mm |
Cash used (since last report) | 1.43 mm | 1.72 mm | 4.93 mm | 5.86 mm | 3.21 mm | 3.84 mm |
Cash remaining | 16.69 mm | 16.40 mm | 13.19 mm | 12.26 mm | 14.91 mm | 14.28 mm |
Runway (months of cash) | 37.1 | 30.3 | 8.5 | 6.7 | 14.8 | 11.8 |
Institutional ownership, Q2 2024
6.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 39 |
Opened positions | 33 |
Closed positions | 6 |
Increased positions | 3 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 6.88 bn |
Total shares | 1.16 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 251.14 k | $1.59 bn |
Baldwin Brothers | 168.63 k | $1.07 bn |
Millennium Management | 119.46 k | $756.18 mm |
BLK BlackRock | 83.41 k | $528.00 mm |
Renaissance Technologies | 74.50 k | $471.59 mm |
GS The Goldman Sachs Group, Inc. | 61.57 k | $389.74 mm |
Geode Capital Management | 53.23 k | $337.00 mm |
NTRS Northern Trust | 49.83 k | $315.41 mm |
Gsa Capital Partners | 48.34 k | $306.00 k |
Marshall Wace | 33.87 k | $214.38 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Jun 24 | Matthew L. Kaplan | Common Stock | Grant | Acquire A | No | No | 0 | 30,000 | 0.00 | 83,760 |
13 Jun 24 | Kenneth Hoberman | Common Stock | Grant | Acquire A | No | No | 0 | 30,000 | 0.00 | 103,140 |
13 Jun 24 | James F Oliviero III | Common Stock | Grant | Acquire A | No | No | 0 | 30,000 | 0.00 | 57,828 |
14 May 24 | Bentsur Ron | Common Stock | Buy | Acquire P | No | No | 6.74 | 1,940 | 13.08 k | 3,246,424 |
10 May 24 | Shay Shemesh | Common Stock | Buy | Acquire P | No | No | 6.32 | 1,113 | 7.03 k | 1,493,068 |
Press releases
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit's Meteoric Rise: Silexion, Nuvectis, Scorpian
19 Sep 24
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit's Meteoric Rise: Silexion, Nuvectis, Scorpian
19 Sep 24
Could Nuvectis Pharma be the Next Summit Therapeutics? A New Report Highlights NXP900's Approach to NSCLC Treatment
16 Sep 24
PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
16 Sep 24
Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data
29 Aug 24